title: Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
abstract: BACKGROUND
  Anti-tumour necrosis factor (anti-TNF) therapy has been associated with reports of rapid severe progression of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). However, reports also exist of favourable responses to anti-TNF therapy in patients with ILD. The aim of this study was to examine the influence of anti-TNF therapy on mortality in patients with pre-existing RA-ILD.
  
  
  METHODS
  Using data from the British Society for Rheumatology Biologics Register, a national prospective observational study, 367 patients with pre-existing RA-ILD were identified (299 treated with anti-TNF therapy and 68 treated with traditional disease-modifying antirheumatic drugs (DMARDs)).
  
  
  RESULTS
  70/299 patients (23%) in the anti-TNF cohort died after a median follow-up of 3.8 years compared with 14/68 (21%) in the DMARD cohort after a median follow-up of 2.1 years. The mortality was 68 deaths/1000 person years (pyrs) (95% CI 53 to 86) in the anti-TNF cohort and 92/1000 pyrs (95% CI 50 to 155) in the DMARD cohort, generating an age- and sex-adjusted mortality rate ratio (aMRR) of 1.26 (95% CI 0.69 to 2.31). After further adjustment for potential confounders, the aMRR fell to 0.81 (95% CI 0.38 to 1.73) for the anti-TNF cohort compared with the DMARD cohort. RA-ILD was the underlying cause of death in 15/70 (21%) and 1/14 (7%) patients in the anti-TNF and DMARD cohorts, respectively.
  
  
  CONCLUSIONS
  The mortality in patients with RA-ILD is not increased following treatment with anti-TNF therapy compared with traditional DMARDs. The proportion of deaths attributable to RA-ILD is higher in patients treated with anti-TNF therapy, although reporting bias may exist.
authors.affiliation: Arthritis Research UK, Epidemiology Unit, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.
authors.forename: W G
authors.initials: WG
authors.lastname: Dixon
authors.forename: K L
authors.initials: KL
authors.lastname: Hyrich
authors.forename: K D
authors.initials: KD
authors.lastname: Watson
authors.forename: M
authors.initials: M
authors.lastname: Lunt
authors.forename: D P M
authors.initials: DP
authors.lastname: Symmons
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000209:etiology / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012042:Registries; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha
references.citation: Arthritis Rheum. 2002 Dec 15;47(6):670-1
references.pmid: 12522843
references.citation: Clin Exp Rheumatol. 2007 Jan-Feb;25(1):23-8
references.pmid: 17417986
references.citation: Ann Rheum Dis. 2003 Sep;62(9):897-900
references.pmid: 12922967
references.citation: BMJ. 2004 Nov 27;329(7477):1266
references.pmid: 15564258
references.citation: J Comput Assist Tomogr. 1999 Nov-Dec;23(6):941-8
references.pmid: 10589572
references.citation: Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv42-3
references.pmid: 16239385
references.citation: Rheumatology (Oxford). 2007 Feb;46(2):350-7
references.pmid: 16908509
references.citation: J Rheumatol. 2007 May;34(5):1151-4
references.pmid: 17444583
references.citation: Ann Rheum Dis. 2003 Aug;62(8):722-7
references.pmid: 12860726
references.citation: Ann Rheum Dis. 2002 Jun;61(6):517-21
references.pmid: 12006324
references.citation: Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):528-35
references.pmid: 9279235
references.citation: Eur Respir J. 1990 Nov;3(10):1206-16
references.pmid: 2090485
references.citation: Arthritis Rheum. 1995 Jan;38(1):44-8
references.pmid: 7818570
references.citation: Curr Opin Pulm Med. 2006 Sep;12(5):346-53
references.pmid: 16926650
references.citation: Am J Epidemiol. 1993 Dec 1;138(11):923-36
references.pmid: 8256780
references.citation: Arthritis Rheum. 2008 Aug;58(8):2228-35
references.pmid: 18668576
references.citation: Scand J Rheumatol. 2007 May-Jun;36(3):172-8
references.pmid: 17657669
references.citation: Rheumatology (Oxford). 2006 Oct;45(10):1312-3
references.pmid: 16935921
references.citation: Chest. 2002 Sep;122(3):1093-6
references.pmid: 12226061
references.citation: J Clin Epidemiol. 1995 Dec;48(12):1503-10
references.pmid: 8543964
references.citation: Arthritis Rheum. 1996 Oct;39(10):1711-9
references.pmid: 8843862
references.citation: Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304
references.pmid: 11790668
references.citation: Arthritis Rheum. 2006 Feb 15;55(1):157-9
references.pmid: 16463430
references.citation: J Rheumatol. 2006 Mar;33(3):622-8
references.pmid: 16511933
references.citation: South Med J. 2006 Jul;99(7):783-4
references.pmid: 16866070
references.citation: Eur J Health Econ. 2008 Jan;8 Suppl 2:S61-86
references.pmid: 18097697
references.citation: Arthritis Rheum. 2010 Jun;62(6):1583-91
references.pmid: 20155830
references.citation: Rheumatology (Oxford). 2006 Aug;45(8):1048-9
references.pmid: 16760195
references.citation: Br J Rheumatol. 1986 May;25(2):206-9
references.pmid: 3708236
references.citation: Rheumatology (Oxford). 2005 Feb;44(2):157-63
references.pmid: 15637039